Ratings Sino Biological,Inc.

Equities

301047

CNE100004Q23

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
76.81 ^CNY	+0.39%		+6.11%	-6.78%

Apr. 28	Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Sino Biological,Inc. completed the acquisition of SignalChem Biotech Inc. from Signalchem Lifesciences Corporation.	CI

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.04 times its estimated earnings per share for the ongoing year.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SINO BIOLOGICAL,INC.	-6.78%	1.35B	-
MODERNA, INC.	+29.81%	48.16B	B-
IQVIA HOLDINGS INC.	-1.11%	41.73B	B
LONZA GROUP AG	+43.45%	41.03B	A
CELLTRION, INC.	-5.26%	28.77B	C
ICON PUBLIC LIMITED COMPANY	+10.23%	25.59B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.95%	18.96B	B
BIO-TECHNE CORPORATION	+8.24%	12.92B	B+
MEDPACE HOLDINGS, INC.	+28.92%	12.03B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.17%	11.77B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes